The Australia Pharmaceutical Membrane Filtration Market was valued at $102.9 Million in 2024 and projected to reach to $179.3 Million by 2029, representing a compound annual growth rate of 11.8%. Australia's pharmaceutical membrane filtration market is positioned for sustained growth, driven by the expansion of the biopharmaceutical sector and increasing investments in manufacturing infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's pharmaceutical membrane filtration market is valued at USD 102.9 million in 2024, with a projected CAGR of 11.8% through 2029, reaching USD 179.3 million by forecast end.
Australia's strengthening biopharmaceutical sector is driving increased adoption of advanced membrane filtration technologies for drug manufacturing, quality assurance, and regulatory compliance.
Australia's commitment to pharmaceutical innovation and stringent regulatory standards are accelerating demand for sophisticated filtration solutions in manufacturing processes and product quality control.
The Australian market benefits from strong healthcare infrastructure, investment in R&D facilities, and growing contract manufacturing organizations requiring advanced filtration capabilities.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | POLYETHERSULFONE MEMBRANE FILTERS (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 13.1% from 2024 to 2029 |
| Largest Segment | MEMBRANE FILTERS (Product) |
| Market Size Base Year (Billions) | ~USD 10.59 (2024) |
| Revenue Forecast (Billions) | ~USD 19.6 (2029) |
| Segments Covered | Product, Type, Technique, Application, Scale Of Operation |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| AIR PURIFICATION | 10.6 | 10.9 | 11.1 | 11.5 | 12.2 | 13.3 | 14.7 | 16.7 | 8.6 |
| CELL SEPARATION | 17.6 | 18.6 | 19.2 | 20.5 | 22.3 | 24.8 | 28.2 | 32.9 | 11.3 |
| FINAL PRODUCT PROCESSING | 45.8 | 48.7 | 50.8 | 54.4 | 59.6 | 66.7 | 76.5 | 89.8 | 12.1 |
| RAW MATERIAL FILTRATION | 35.5 | 37.6 | 39.1 | 41.7 | 45.5 | 50.8 | 58 | 67.8 | 11.7 |
| WATER PURIFICATION | 15 | 15.8 | 16.3 | 17.3 | 18.8 | 20.8 | 23.6 | 27.5 | 11 |
| TOTAL | 124.4 | 131.6 | 136.4 | 145.4 | 158.4 | 176.3 | 201 | 234.7 | 11.5 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| VALMET CORPORATION | Finland | Public Company | Biomaterial Solutions and Services (pulp, paper, tissue, packaging lines and lifecycle services),Process Performance Solutions – Automation systems and industrial applications,Process Performance Solutions – Flow control (valves, pumps, valve automation), |
| MERCK KGAA | United States | Public Company | Life Science (reagents, consumables, devices, instruments, software, services, bioprocessing solutions, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals across oncology, rare diseases, neurology and immunology, fertility, cardiovascular, metabolic and endocrinological disorders),Electronics (semiconductor materials, specialty gases, delivery equipment, display and photonics materials), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (Bioprocessing and Single-Use Solutions),Life Sciences (Instruments and Consumables),Diagnostics (Clinical Instruments and Consumables), |
| SARTORIUS AG | United States | Public Company | Bioprocess solutions (bioreactors, cell culture, process filtration & chromatography, fluid management),Lab products & services (lab filtration, weighing, pipettes, microbiological testing, lab water, OEM),Analytical & cell analysis solutions (BLI, cytometry screening, PAT & data analytics, live-cell imaging, SPR, cell selection), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions (reagents, instruments, consumables),Analytical Instruments,Specialty Diagnostics, |
| 3M COMPANY | United States | Public Company | Safety and Industrial,Transportation and Electronics,Consumer, |
| PARKER HANNIFIN CORPORATION | United States | Public Company | Industrial motion and control (hydraulics, pneumatics, electromechanical),Sealing, adhesives, and thermal management,Filtration and fluid management, |
| REPLIGEN CORPORATION | United States | Public Company | Filtration and cell retention (XCell ATF, TangenX, KrosFlo, TFDF, ProConnex),Chromatography systems, columns, and resins (OPUS, KRM, resins, AVIPure),Process analytics and PAT (PATsmart MAVERICK/MAVEN/REBEL/ZipChip, SoloVPE/FlowVPE), |
| ASAHI KASEI CORPORATION | Japan | Public Company | Advanced materials for semiconductors and electronics,Battery separators and energy-related materials,Membranes and process systems, |
| EATON CORPORATION PLC | Ireland | Public Company | Electrical Americas,Electrical Global,Aerospace, |
| GEA GROUP | Germany | Public Company | Separation & Flow Technologies (separators, decanters, valves, pumps, homogenizers),Liquid & Power Technologies (brewing, liquid processing, filling, concentration, fermentation),Food & Health Technologies (meat, poultry, seafood, vegan processing; slicing; pharma equipment), |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, hardware, components),Display glass substrates (LCD and OLED),Specialty materials (mobile, semiconductor optics, sunglasses, shielding), |
| DONALDSON COMPANY, INC. | United States | Public Company | Mobile Solutions,Industrial Solutions,Life Sciences, |
| SAINT-GOBAIN | France | Public Company | Plasterboard and interior systems (Placo, Rigips, Gyproc, ceilings brands),Insulation solutions (Isover, CertainTeed, Izocam),Mortars and construction chemicals (Weber, Chryso, GCP), |
Valmet Corporation is a Finnish public company founded in 1750 with 18,370 employees. The company has a long-established history in industrial manufacturing and services.
Merck KGaA is a United States-based public company with roots dating to 1668 and 59,077 employees. The company operates as a diversified pharmaceutical and chemical enterprise.
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. The company operates across multiple industrial and life sciences sectors.
Sartorius AG is a United States-based public company founded in 1870 with 14,242 employees. The company specializes in laboratory and pharmaceutical equipment.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a leading provider of life sciences and analytical instruments.
3M Company is a United States-based public company founded in 1902 with 60,500 employees. The company manufactures a diverse portfolio of products across multiple industries.
Parker Hannifin Corporation is a United States-based public company founded in 1917 with 57,950 employees. The company specializes in motion and control technologies.
Repligen Corporation is a United States-based public company founded in 1981 with 2,000 employees. The company provides bioprocessing solutions for the life sciences industry.
Asahi Kasei Corporation is a Japanese public company founded in 1922 with 47,895 employees. The company operates across chemicals, materials, and healthcare sectors.
Eaton Corporation PLC is an Ireland-based public company founded in 1911 with 97,303 employees. The company provides diversified industrial power management solutions.
GEA Group is a German public company founded in 1881 with 19,670 employees. The company specializes in process technology and equipment for various industries.
Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees. The company manufactures specialty glass, ceramics, and related materials.
Donaldson Company, Inc. is a United States-based public company founded in 1915 with 15,000 employees. The company manufactures filtration systems and related products.
Saint-Gobain is a French public company founded in 1665 with 158,616 employees. The company is a global leader in building materials and high-performance materials.
Australia's pharmaceutical membrane filtration market was valued at USD 102.9 million in 2024 and is expected to reach USD 179.3 million by 2029.
Australia's pharmaceutical membrane filtration market is projected to grow at a compound annual growth rate (CAGR) of 11.8% from 2024 to 2029.
Australia's growth is driven by increasing biopharmaceutical manufacturing, stringent regulatory requirements, rising quality standards, and investment in pharmaceutical infrastructure modernization.
Australia's market is expected to grow by USD 76.4 million, representing a 74.2% increase from 2024 to 2029.
Australia serves as a key innovation hub in Asia Pacific with advanced manufacturing capabilities, strong regulatory frameworks, and significant investment in biopharmaceutical development.
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global pharmaceutical membrane filtration market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical membrane filtration market. The secondary sources used for this study include American Membrane Technology Associations (AMTA), European Membrane Society (EMS), American Association of Pharmaceutical Scientists (AAPS), Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), Parenteral Drug Association (PDA), Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, National Institutes of Health (NIH), World Health Organisation (WHO), Indian Pharmaceutical Association (IPA), International Society for Pharmaceutical Engineering (ISPE), BioProcess International Magazine, BioPharm International, Journal of Bioprocessing and Biotechniques, BioPlan Associates, ScienceDirect, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Extensive primary research was conducted after acquiring basic knowledge about the global pharmaceutical membrane filtration market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the pharmaceutical membrane filtration market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Membrane filtration is a process wherein solid particles present in a suspension are separated from a liquid or gas by employing membrane filters such as filter sheets, filter cartridges, or filter papers. These membrane filters are used to retain solids, thus allowing liquids to pass through. Membrane filters are used in pharmaceutical and biopharmaceutical manufacturing processes.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Pharmaceutical Membrane Filtration Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report